Key Takeaways and Future Considerations in Advanced DTC Management

In this closing segment, Dr. Greg Randolph distills key lessons for clinicians managing patients with differentiated thyroid cancer (DTC), particularly those whose disease progresses over time. He emphasizes that optimal care depends on a truly multidisciplinary model, involving surgeons, endocrinologists/endocrine oncologists, and medical oncologists working in close coordination rather than in silos.

For patients with metastatic disease and local–regional recurrence, surgeons help determine whether reoperation or ablative approaches are safe and beneficial. Endocrinologists guide TSH suppression, calcium/vitamin D management, radioactive iodine use, and consideration of redifferentiation strategies. Medical oncologists and endocrine oncologists lead systemic therapy selection and sequencing, often informed by NGS testing.

Dr. Randolph also highlights the importance of smooth transitions between specialties, communicating vocal cord status, imaging timing, biochemical parameters, and disease trajectory. Early involvement of medical oncology, even before systemic therapy is needed, helps ensure that when progression occurs, patients receive timely, well-coordinated, and personalized care.

Supported in part by Eisai, content independently produced by OncLive.